ByTrending Posts
How Will Ambience Healthcare’s $243M Series C Propel…
Key Highlights Transforming Clinical Documentation and Workflow with Ambient AIAmbience’s platform listens passively to clinical encounters, generating structured,…
What Impact Will the Trump Administration’s Private Health…
Key Highlights Transforming Access to Health Data Through Private Sector-Led InnovationThe Trump Administration aims to modernize healthcare with…
Can Viridian Therapeutics’ $70M Collaboration with Kissei Pharmaceutical…
Key Highlights Strategic Collaboration Combines Strengths to Advance TED Treatment in JapanViridian Therapeutics partners exclusively with Kissei Pharmaceutical…
Can Merck’s $3 Billion Restructuring Drive Sustainable Growth…
About MerckMerck & Co., Inc. (MSD outside US & Canada) is a global biopharmaceutical company dedicated to innovating…
Is Bristol Myers Squibb’s $300M Immunology Venture with…
Key Highlights About Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical leader focused on innovative medicines in oncology, immunology,…
How Is GSK’s Robust Q2 2025 Growth Powering…
Key Highlights Specialty Medicines Fuel Strong Market MomentumGSK’s specialty portfolio, notably in Respiratory, Immunology & Inflammation (+10%) and…
Is Mayo Clinic’s NVIDIA Blackwell-Powered DGX SuperPOD the…
Key Highlights NVIDIA Blackwell Infrastructure: High-Performance Compute for Healthcare AIThe NVIDIA DGX SuperPOD system delivers state-of-the-art, scalable AI…
Is Aptitude’s $9M BARDA Partnership and Metrix Filovirus…
Key Highlights BARDA Partnership Accelerates Filovirus Diagnostic InnovationAptitude’s second collaboration with BARDA brings $9 million in new federal…
Is Aidoc’s $150M Bet on CARE™ and aiOS™…
Key Highlights CARE™ Foundation Model Redefining Standards in Clinical AIAidoc’s CARE™ model—now backed by $150 million in new…
Trending Posts
Latest Stories
How Roche’s $55 Million Bet on Manifold Bio’s AI Brain-Shuttle Platform Unlock the Next Trillion-Dollar Neuroscience Opportunity?
Key Highlights• Roche deepens its AI-first drug discovery strategy with a foundational partnership targeting blood-brain…
Will Lilly’s AI Supercomputer with NVIDIA Become the Breakthrough That Redefines Competitive Timelines in Drug Development?
• Lilly partners with NVIDIA to build what it calls the most powerful AI supercomputer…
Could Merck’s USD 349M Collaboration with Variational AI and Its Enki™ Platform Mark a Turning Point for Generative-AI-Designed Small Molecules?
Key Highlights A Strategic Alliance Targeting Hard-to-Crack Therapeutic SpaceVariational AI announced a major collaboration with…
Could Excelsior Sciences’ $95M AI Surge Redefine How Fast Small-Molecule Drugs Reach the Market?
Key Highlights • $95M funding round positions Excelsior to compress multi-month chemistry cycles into weeks,…
Gallery
